Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Real-World Evidence Comparison

How Each Drug Works

Sildenafil and alprostadil produce erections through entirely different biological pathways. Sildenafil blocks phosphodiesterase type 5 (PDE5), preserving cyclic GMP in penile smooth muscle and amplifying nitric-oxide-driven vasodilation. Alprostadil is synthetic prostaglandin E1 (PGE1) that binds EP receptors directly, raising cyclic AMP independent of nitric oxide. This mechanistic difference explains why alprostadil can rescue men who have minimal endogenous nitric oxide production, such as those with severe vascular or post-prostatectomy neurogenic ED.

Sildenafil Mechanism

When a man is sexually aroused, nitric oxide released from nerve endings and endothelial cells activates guanylate cyclase, producing cyclic GMP. Cyclic GMP relaxes the smooth muscle of the corpus cavernosum, allowing blood to fill the lacunar spaces. PDE5 degrades cyclic GMP and terminates the erection. Sildenafil inhibits PDE5 with an IC50 of roughly 3.5 nM, extending the duration of cyclic GMP activity. Without sexual stimulation, sildenafil alone does not produce an erection. This is a clinically meaningful point for men who have limited sexual spontaneity or significant performance anxiety.

Alprostadil Mechanism

Alprostadil bypasses the nitric oxide pathway entirely. Delivered locally by injection into the corpus cavernosum or by absorption through the urethral mucosa, PGE1 binds EP2 and EP4 receptors, activating adenylyl cyclase and raising intracellular cyclic AMP. This relaxes smooth muscle directly. Because the stimulus is pharmacological rather than neural, alprostadil produces erections even in men with complete pelvic nerve damage, such as post-radical-prostatectomy patients. Onset is 5 to 20 minutes. No sexual stimulation is required.

Landmark Clinical Trial Evidence

The two most cited head-to-period randomized controlled trials for these agents come from the same journal in consecutive years, giving clinicians a clean evidentiary foundation.

Goldstein et al. (NEJM 1998): Sildenafil

Goldstein and colleagues published the key dose-escalation trial of sildenafil in the New England Journal of Medicine in 1998 [1]. The study enrolled 532 men with ED of organic, psychogenic, or mixed cause. Over 24 weeks, sildenafil at doses from 25 mg to 100 mg improved the International Index of Erectile Function (IIEF) erectile function domain score from a baseline of 12 to 20 points, compared with a change from 13 to 14 in the placebo group (P<0.001). Sixty-nine percent of sexual attempts were successful in the sildenafil group versus 22% in the placebo group. Adverse events were dose-related and mostly mild: headache (16%), flushing (10%), dyspepsia (7%), and transient bluish visual tinge (3%).

Linet et al. (NEJM 1996): Alprostadil Injection

Linet and colleagues published the registration RCT for intracavernous alprostadil (Caverject) in NEJM in 1996 [2]. The trial enrolled 296 men with ED, primarily of organic origin. At home, 94% of alprostadil injections produced erections sufficient for intercourse, versus 9% of placebo injections. At the 6-month mark, 87% of men who entered the open-label extension continued to use the drug. Penile pain occurred in 37% of men, though it was rated mild to moderate and did not cause the majority to discontinue. Priapism occurred in 1% of patients, a number that guides current dose titration protocols.

MUSE Trial Data

The intraurethral MUSE (Medicated Urethral System for Erection) formulation showed lower response rates than injection in registrational data. In the key Williams et al. Home-use trial, 43% of men using MUSE 125 to 1,000 mcg achieved an erection sufficient for intercourse, versus 9% of placebo [3]. Clinic-based titration raised response rates to about 65% in some subgroups. MUSE is generally positioned below Caverject in efficacy but above oral agents for men who cannot tolerate injections.

Real-World Effectiveness: How Trials Translate to Practice

Randomized trial populations are selected and motivated. Real-world cohorts show meaningfully different numbers.

Sildenafil Real-World Adherence

A retrospective analysis of 10,968 men newly prescribed PDE5 inhibitors found that only 41% refilled their prescription within 12 months [4]. Men with diabetes, post-prostatectomy status, and psychological comorbidities had the highest dropout rates. The most common reason cited in post-market surveys was insufficient rigidity, pointing to a subset who will eventually need second-line therapy.

Alprostadil Real-World Dropout

Injection therapy has well-documented attrition. Long-term observational data show that 30 to 50% of men who are successfully trained on intracavernous injection stop using it within 12 to 24 months, citing injection discomfort, inconvenience, and partner reluctance [5]. Men who persist beyond 6 months tend to continue for years: one 5-year follow-up found a 68% continuation rate in those who reached the 6-month mark.

Post-Prostatectomy ED: A Specific Real-World Population

Post-radical-prostatectomy ED is the population where alprostadil shows its clearest advantage over sildenafil. A prospective trial by Montorsi and colleagues found that early penile rehabilitation with alprostadil injection significantly increased spontaneous erection recovery rates at 6 months compared with no therapy (67% vs. 20%) [6]. Sildenafil has been studied in penile rehabilitation but the evidence for long-term recovery of spontaneous function is weaker, particularly in bilateral nerve-sparing cases.

Head-to-Head Comparison: Efficacy by ED Subtype

No single large RCT has directly randomized men to oral sildenafil versus intracavernous alprostadil in the same trial. The comparison below synthesizes separate-arm data across published trials and observational registries.

Vasculogenic ED

Sildenafil produces a 60 to 70% response in mild-to-moderate vasculogenic ED [1]. Alprostadil injection achieves 70 to 80% response even in moderate-to-severe cases because it bypasses the nitric oxide deficit that accompanies endothelial dysfunction [2]. For men with an ABI (ankle-brachial index) <0.8 or known peripheral vascular disease, alprostadil may be the more reliable first option.

Diabetic ED

Diabetes impairs both nitric oxide signaling and the neural arc controlling erection. Sildenafil response rates in diabetic men fall to approximately 50 to 60%, compared with 70% in the general ED population [7]. Alprostadil intracavernous injection maintains a 70 to 75% response in diabetic men because its mechanism does not depend on preserved nitric oxide pathways. The ADA Standards of Care in Diabetes note that PDE5 inhibitors remain first-line even in diabetic men but acknowledge higher failure rates [8].

Psychogenic ED

Psychogenic ED responds well to sildenafil. Because the nitric oxide system is largely intact, PDE5 inhibition is sufficient, and the pill-based administration carries less psychological burden than self-injection. Alprostadil is rarely used first-line in purely psychogenic ED and is generally reserved for men who develop secondary performance anxiety severe enough to prevent any arousal-based erection.

Neurogenic ED (Spinal Cord Injury, Post-Prostatectomy)

This is alprostadil's home terrain. Men with complete sacral spinal cord lesions or post-prostatectomy nerve injury have absent or severely impaired reflexogenic erections. Sildenafil requires at least partial neural input; alprostadil does not. A Cochrane review of ED treatments after radical prostatectomy found that intracavernous alprostadil produced the highest rates of erection sufficient for intercourse in nerve-damaged men [9].

Safety and Tolerability

Sildenafil Safety Profile

Sildenafil's most clinically significant risk is cardiovascular. The drug is absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate) due to severe synergistic hypotension [1]. Sildenafil also interacts with alpha-blockers: the FDA label specifies a 4-hour interval between sildenafil and doxazosin. The Princeton Consensus III guidelines stratify men with cardiovascular disease into low, intermediate, and high-risk groups before prescribing any ED therapy [10]. Vision loss from non-arteritic anterior ischemic optic neuropathy (NAION) has been reported but remains rare, with an estimated incidence of approximately 2.5 per 100,000 prescriptions.

Common adverse effects in the Goldstein trial were mild: headache (16%), flushing (10%), dyspepsia (7%) [1]. These are largely predictable from PDE5 expression in vascular smooth muscle and the gut.

Alprostadil Safety Profile

Alprostadil's main local adverse effects are penile pain and the risk of prolonged erection. In the Linet trial, 37% of men reported penile pain with injection, though most rated it mild [2]. Priapism (erection lasting more than 4 hours) occurred in roughly 1% of patients in controlled settings; real-world estimates are similar. Men must be counseled to seek emergency care for any erection lasting longer than 4 hours, because ischemic priapism causes corporal fibrosis within 24 to 48 hours.

Penile fibrosis and Peyronie's-like plaques develop in approximately 2 to 3% of long-term injection users. This is lower with proper injection technique and rotation of injection sites.

MUSE carries a risk of urethral burning (12 to 32%), hypotension (3%), and dizziness (4%) from systemic absorption. A small amount of alprostadil does transfer to the female partner's vagina during intercourse; condoms are recommended when the female partner is pregnant.

Drug Interactions Compared

| Issue | Sildenafil | Alprostadil | |---|---|---| | Nitrate contraindication | Absolute | None | | Alpha-blocker interaction | Yes (timing interval required) | Mild additive hypotension possible | | Anticoagulant interaction | None significant | Increased bruising at injection site | | CYP3A4 inhibitors (ketoconazole, ritonavir) | Increase sildenafil AUC up to 11-fold | Not applicable | | Cardiovascular risk | Low in low-risk patients | Very low; used in cardiac rehab patients |

Switching From Sildenafil to Alprostadil

When to Consider Switching

Switching is appropriate after two to three adequate trials of sildenafil at maximum tolerated dose (100 mg with at least 60 minutes pre-sex and an empty stomach). The American Urological Association (AUA) 2018 ED guideline defines adequate trial as at least four attempts at the highest tolerated dose before declaring PDE5 inhibitor failure [11]. Men who meet this criterion should be counseled about second-line options, including alprostadil injection and vacuum erection devices.

Switching should also be considered in:

• Men with absolute nitrate contraindications who cannot tolerate sildenafil's drug interaction burden
• Post-prostatectomy men undergoing penile rehabilitation within 6 to 12 months of surgery
• Men with severe diabetes or vascular disease and documented PDE5 inhibitor failure
• Men who report adequate erections with sildenafil but cannot achieve satisfactory rigidity for their specific anatomical situation

How the Switch Is Managed Clinically

Sildenafil has a half-life of about 4 hours and does not need to be tapered. The transition to alprostadil injection requires in-office dose titration, starting at 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, increasing in 5 mcg increments until a satisfactory erection is achieved without more than 60 minutes duration. The AUA recommends that the first injection always be administered in the office so the clinician can manage prolonged erection if it occurs [11].

Men switching to MUSE should be counseled that the response rate is lower than injection and that the initial dose should be titrated in a medical setting using a urine void to activate the suppository correctly.

Combination Therapy

Some men use low-dose sildenafil (25 to 50 mg) combined with low-dose alprostadil MUSE (125 to 250 mcg) when neither agent alone provides sufficient rigidity. A small RCT by Nehra and colleagues found that combination therapy produced 65% satisfactory intercourse versus 35% for MUSE alone and 40% for sildenafil alone in PDE5 inhibitor partial responders [12]. Combination use requires careful monitoring for hypotension, since both agents lower blood pressure through separate mechanisms.

Patient Selection: Who Does Best on Each Drug

Sildenafil Is the Better Choice When

• ED is mild to moderate and of psychogenic or mixed cause
• The man has intact nitric oxide signaling (younger, no diabetes, no severe vascular disease)
• Spontaneity and ease of administration matter to the couple
• Cost is a significant factor (generic sildenafil can cost under $2 per tablet at major pharmacies)
• The man is already on cardiovascular monitoring and not taking nitrates

Alprostadil Is the Better Choice When

• Two or more PDE5 inhibitors have failed at maximum dose
• ED is post-prostatectomy, spinal cord injury-related, or otherwise neurogenic
• The man has diabetes with severe autonomic neuropathy
• Nitrate therapy is ongoing and sildenafil is contraindicated
• Early penile rehabilitation after nerve-sparing prostatectomy is the clinical goal

Cost and Access Considerations

Generic sildenafil became widely available in the United States after the primary Pfizer patent expired in 2017. Retail pricing at pharmacy chains ranges from $0.90 to $4 per 100 mg tablet, with GoodRx coupons often bringing 100 mg generic sildenafil below $1.50. Caverject (alprostadil injection) costs $25, $75 per single-use vial depending on dose and pharmacy, and MUSE suppositories range from $60, $90 per unit without insurance. For men who require frequent use, the cost differential is substantial: 30 tablets of generic sildenafil may cost less than two Caverject vials.

Insurance coverage varies widely. Medicare Part D covers both agents, but prior authorization for alprostadil typically requires documented PDE5 inhibitor failure. The FDA approved the first generic sildenafil tablets in December 2017 [13], and multiple generic manufacturers now supply the market, keeping prices low.

As of the 2024 AUA formulary guidance, generic sildenafil 20 mg tablets (marketed as Revatio for pulmonary hypertension) represent an even lower-cost option: four 20 mg tablets equal one 80 mg sildenafil dose, and the 20 mg tablets may be priced significantly below the 50 mg or 100 mg ED-labeled tablets.